誠達藥業(301201.SZ):現有左旋肉鹼系列產品(不含中間體L-肉鹼腈化物)產能1409噸
格隆匯3月15日丨誠達藥業(301201.SZ)於2023年3月13日14:00-15:00接受機構調研時表示,公司左旋肉鹼產品的主要功效有:提高運動耐力、控制體重、保護心臟健康、緩解慢性疲勞、抗衰老、男性生殖功能健康、孕婦及嬰幼兒營養補充等。左旋肉鹼常被作為食品添加劑用於保健產品、功能性飲料、嬰幼兒配方奶粉等,以及作為藥物用於治療慢性腎功能衰竭、心肌病、冠心病、有機酸血癥等疾病。此外,在飼料添加劑領域,左旋肉鹼可用於促進動物生長、提高肉質品質、增強繁殖能力等。
公司現有左旋肉鹼系列產品(不含中間體L-肉鹼腈化物)產能1409噸,國內主要競爭對手包括廣州龍沙、東北製藥、開原亨泰、遼寧科碩等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.